Newsletters

[Communications Biology] Scientists demonstrated that suppress of cholesterol synthases FDFT1 or SQLE enhances colorectal cancer metastasis and stemness through impairing ER stress and degrading PDIA4 or SYVN1 individually.

[Oncogene] Investigators reported that PKM2 expression is upregulated in breast CSCs (BCSCs). LINC00887 maintains the self-renewal of BCSCs by promoting PKM2 splicing and reprogramming glucose metabolism.

[NPJ Breast Cancer] Scientists investigated progesterone receptor-dependent transcriptional programs such as the unfolded protein response that can be leveraged to target CSCs in Y537S estrogen receptor gene (ESR1)-mutant breast cancer.

[Cell Death & Disease] Researchers identified a noncanonical, nuclear role of hexokinase 2 that couples systemic hyperglycemia to MYC-driven glycolysis and stemness in bladder cancer.

[Cell Death & Disease] Several new specific markers of dormant CSCs, such as p27, CD13, QSOX1, Survivin, GPD1 and BEX2, have been identified, which offer hope for targeted therapy. The authors examine recent significant findings regarding tumor stem cell dormancy in both experimental and human disease models.

[Stem Cell Research & Therapy] The authors highlight unresolved issues and further outline key contextual factors, including tumor-intrinsic, microenvironmental, systemic, and metastatic cues, that shape CSC metabolism and help explain the divergent observations reported across studies.

[Experimental & Molecular Medicine] Scientists outline emerging mechanisms by which oxidoreductases couple metabolic flux to epigenetic landscapes that maintain or dissolve stemness.

[Leukemia] MD-265 is a PROTAC that recruits cereblon, degrades MDM2, restores p53 and induces apoptosis. Researchers tested MD-265 in ex vivo cultures of 105 primary leukemic stem cells.

[Communications Biology] In an AML murine model, MAR-3.6.2, a novel allosteric inhibitor that binds in a cryptic pocket in the C-terminal domain of RAN, reduced leukemia burden, prolonged survival, and decreased leukemia stem cell frequency in secondary transplants.

[Richmond News] For many, Dr. Julia Levy was known as the woman who helped shape the modern life sciences industry. While a professor at the University of British Columbia, her lab focused on cancer immunology and pioneered a treatment that uses light to activate abnormal cells to treat cancers.

[UT Health San Antonio] UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer study, marking a pivotal moment for science and patient-centered cancer care in San Antonio and South Texas.

[Proceedings of the National Academy of Sciences of the United States of America] Using a clinically relevant closed-head weight-drop mouse model, scientists identified mtDNA-specific damage and increased expression of innate inflammatory markers in the cerebral cortex during the acute mild traumatic brain injury phase.